Research Output per year
Research Output per year
Fingerprint
Dive into the research topics where Raushan T Kurmasheva is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 3 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output
-
Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium
Gill, J., Zhang, W., Zhang, Z., Roth, M., Harrison, D. J., Rowshan, S., Erickson, S., Gatto, G., Kurmasheva, R., Houghton, P., Teicher, B., Smith, M. A., Kolb, E. A. & Gorlick, R., Oct 1 2020, In: Pediatric Blood and Cancer. 67, 10, e28606.Research output: Contribution to journal › Article › peer-review
-
Evaluation of eribulin combined with irinotecan for treatment of pediatric cancer xenografts
Robles, A. J., Kurmasheva, R. T., Bandyopadhyay, A., Phelps, D. A., Erickson, S. W., Lai, Z., Kurmashev, D., Chen, Y., Smith, M. A. & Houghton, P. J., Jun 15 2020, In: Clinical Cancer Research. 26, 12, p. 3012-3023 12 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium
Kurmasheva, R. T., Bandyopadhyay, A., Favours, E., Pozo, V. D., Ghilu, S., Phelps, D. A., McGeehan, G. M., Erickson, S. W., Smith, M. A. & Houghton, P. J., Jul 1 2020, In: Pediatric Blood and Cancer. 67, 7, e28284.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium
Harrison, D. J., Gill, J. D., Roth, M. E., Zhang, W., Teicher, B., Erickson, S., Gatto, G., Kurmasheva, R. T., Houghton, P. J., Smith, M. A., Kolb, E. A. & Gorlick, R., Jun 1 2020, In: Pediatric Blood and Cancer. 67, 6, e28222.Research output: Contribution to journal › Article › peer-review
-
In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models—A report from the Pediatric Preclinical Testing Consortium
Kurmasheva, R. T., Erickson, S. W., Earley, E., Smith, M. A. & Houghton, P. J., Feb 2021, In: Pediatric Blood and Cancer. 68, 2, e28772.Research output: Contribution to journal › Article › peer-review
Press / Media
-
University of Texas Health Science Center at San Antonio: CPRIT Awards Mays Cancer Center More Than $10.3 Million
Raushan T Kurmasheva, Luiz O Penalva, Dmitri N Ivanov, Manjeet K Rao, Mingjiang Xu & Ruben Mesa
8/21/20
1 item of Media coverage
Press/Media: Press / Media
-
Preclinical drug development for childhood cancers
Peter J Houghton & Raushan T Kurmasheva
11/28/19
1 item of Media coverage
Press/Media: Press / Media
-
Innovative genomics and bioinformatics research at the Greehey Institute
Yidong Chen, Manjeet K Rao, Peter J Houghton & Raushan T Kurmasheva
6/18/19
1 item of Media coverage
Press/Media: Press / Media
-
Epizyme : to Present New Scientific Data on the Role of HMT Inhibitors in Cancer
11/4/15
2 items of Media coverage
Press/Media: Press / Media
-
Epizyme to Present New Scientific Data on the Role of HMT Inhibitors in Cancer
11/4/15
31 items of Media coverage
Press/Media: Press / Media